In vitro susceptibility of Mycobacterium avium to a new macrolide (RU-28965).
The in vitro susceptibility of Mycobacterium avium to RU-28965 alone and in combination with rifampin, isoniazid, and sulfametoxipiridazine was studied by the agar dilution method. The synergistic effect of the RU-28965 with rifampin has been demonstrated. At a concentration of 16 micrograms/ml or lower of RU-28965, 100% of M. avium strains were inhibited. If 2 micrograms/ml of rifampin is added the MIC of RU-28965 is lowered to 0.25 microgram/ml.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004347:Drug Interactions; D007538:Isoniazid / Q000494:pharmacology; D007933:Leucomycins / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009162:Mycobacterium avium / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology; D013421:Sulfamethoxypyridazine / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D007933:Leucomycins; D013421:Sulfamethoxypyridazine; D007538:Isoniazid; D012293:Rifampin